Replies to post #74893 on Biotech Values

[iwfal]

Clark, do you care to retract this statement in light of today’s thread on the iVillage ZGEN board?

Why? My erroneous understanding of the PROVE-3 protocol is fairly minor in regards to this - the relapse rate without SoC is clearly a lot higher than when combined with SoC. The point being that not all viral-count-below-thresholds are equal - which is some clinical data in counterpoint to your thesis that if you get the count low enough the immune system can innately (i.e. without a booster) kick out the rest. (I fully agree it is not an absolute disproof - but then what is in clinical trials?)

Key data - T24/P24 had 2x the relapse rate of T12/PR24 (53% vs 28%). And it would probably be even more dramatic if it were Ifn that were missing instead of ribavirin.

As for:

I would immodestly suggest that you reread #msg-36466697 and do a little more homework before you make further predictions regarding the HCV arena

It's MoA and pre-clinical data, and, per your own sentiments, thus somewhat suspect. That said, I'll trade you:

I'll come up to speed on replicon experiments if you catch up on how the HVC virus hides from the immune system. We both have our holes. Mine somewhat larger than yours inre HCV - but shear size is not the only factor.